Brammer has an experienced leadership team and exceptional
From Left to Right: Executive Vice President of Client Management Nicole O'Brien, Ph.D.; Chief Scientific Officer and Founder Richard Snyder, Ph.D.; Executive Vice President and General Counsel Lana Gladstein; Vice President and Site Head Dana Alexander; Chief Operations Officer Chris Murphy; Executive Vice President of Human Resources Rebecca Shocklee; Chief Financial Officer Steve Favaloro; Vice President and Site Head Larry Pitcher; President, Chief Executive Officer and Founder Mark Bamforth; Vice President of Process Development Susan D'Costa
Mark R. Bamforth
President and Chief Executive Officer, Founder
In 2015 Mark founded Brammer Biopharmaceuticals, a cell and gene therapy CMO, subsequently merged in March 2016 with Florida Biologix to create Brammer Bio. Previously, Mark founded Gallus BioPharmaceuticals, a premier CDMO delivering clinical and commercial mammalian based biopharmaceuticals which was sold to DPx Holdings B.V. (Patheon) in September 2014. Mark spent 22 years in the UK and USA, running global operations and a pharmaceutical CMO business for Genzyme Corp. His work at Genzyme included supporting cell therapy and gene therapy clinical trials resulting in the first FDA approval of a cell therapy product. Mark began his career as a petroleum engineer, exploring for North Sea oil, then as a chemical engineer in the whisky industry. He serves on the MassBio Board and is a founding trustee of the Saltire Foundation. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.
Richard O. Snyder, Ph.D.
Chief Scientific Officer, Founder
Dr. Snyder was the founder of Florida Biologix, which was spun out of the University of Florida in 2015 and merged with Brammer Biopharmaceuticals in 2016 to create Brammer Bio. Dr. Snyder has been investigating virus biology, vector development, cGMP manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 32 years, and was a member of teams who developed novel viral vector-based human gene therapies. Dr. Snyder was an associate professor of Molecular Genetics and Microbiology, and director of Biotherapeutic Programs at the University of Florida; an assistant professor of pediatrics at Harvard Medical School; and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen where he was engaged in the development of gene transfer vector and vaccine technology, along with therapeutic applications. Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, received his doctoral degree in Microbiology from The State University of New York at Stony Brook, and obtained his B.A. in biology from Washington University in St. Louis. Dr. Snyder has authored over 60 publications and 8 US patents.
Christopher K. Murphy
Chief Operations Officer
Christopher Murphy is Chief Operations Officer for Brammer Bio. Chris has more than 30 years of experience in biopharmaceutical manufacturing, process development, plant operations, and quality system remediation. Prior to joining Brammer Bio, Chris served as General Manager for the Sanofi-Genzyme Allston Landing site overseeing operations and leading an integrated remediation program associated with the consent decree. In addition to his role in Allston, Chris was Site Head for Genzyme’s gene therapy operation in San Diego, CA and led commercial manufacturing of recombinant protein products in Framingham, MA. Prior to joining Genzyme, Chris was responsible for US contract manufacturing at Bioreliance (Rockville, MD), focused on viral vector manufacturing and cell banking. Chris began his career at American Cyanamid/Wyeth (now Pfizer) in Pearl River, NY. In his 10 years with the company, he held positions in quality control, viral vaccine development, and bulk manufacturing. He earned his M.Sc. in biochemistry at New York Medical College, and his B.Sc. in biology at Rutgers University.
Steven J. Favaloro
Chief Financial Officer
Steve Favaloro is Chief Financial Officer of Brammer Bio. In this role, he oversees the company’s accounting, tax, treasury, financial planning, and IT functions. Prior to joining Brammer, Steve held various FP&A roles at Bruker Corporation, including his last assignment supporting multiple manufacturing operations in Germany and Switzerland. Prior to Bruker, Steve began his career at Millipore Corporation, where he spent time in various accounting and FP&A roles leading up to, and after, the acquisition of Millipore by Merck KGaA. Steve has received his B.A. in Economics from Boston College and his Masters in Science, Finance and MBA from the Carroll School of Management at Boston College.
Chief Quality Officer
Steve Falcone is the Chief Quality Officer for Brammer Bio. He joined Brammer from Sanofi where he was the VP of Quality with responsibilities for three manufacturing sites in their Biologics network. Prior to Sanofi, Steve was with Amgen where he had key roles, which included Head of External Affairs in the International Quality organization and General Manager of two of Amgen's facilities responsible for viral-based cancer therapy. Steve's additional experience includes Quality roles at Boehringer-Ingelheim Fremont (formerly Amgen Fremont) in California where he was their Director of Quality Operations. Prior to that, Steve served as the Head of Technical Operations at Solstice Neurosciences, as well as other Quality roles at Bayer at their biotechnology campus in Berkeley. A chemistry graduate of UC Berkeley, Steve has been in the industry for over 23 years.
Rebecca A. Shocklee
Executive Vice President, Human Resources
Rebecca Shocklee is Executive Vice President of Human Resources (HR) and Officer of Brammer Bio. In this role, she oversees all facets of HR, as well as Internal Communications. Prior to joining Brammer, Rebecca held various roles including Senior Director of Human Resources for Gallus BioPharmaceuticals and Global HR Business Partner for Merck KGaA. Rebecca has over 20 years of experience in the human resources field. She earned her B.S. degree from Illinois State University and is SPHR certified.
Lana A. Gladstein
Executive Vice President and General Counsel
Lana Gladstein is Executive Vice President, General Counsel and Officer of Brammer Bio. Prior to joining Brammer Bio in 2017, Lana was a partner at the law firms of Nutter McClennen & Fish LLP and Pepper Hamilton LLP, where she represented biotechnology, pharmaceutical, and medical device companies in IP litigation, contested matters at the USPTO, IP strategy, and licensing transactions. Lana received her B.A. degree in Biology from Brandeis University and her J.D. from Northeastern University School of Law.
Nicole W. O'Brien, Ph.D.
Executive Vice President, Client Management
Nicole O’Brien is Executive Vice President of Client Management for Brammer Bio. Prior to joining Brammer, Nicole was employed by FUJIFILM Diosynth Biotechnologies, Inc. as director of business development, and later as senior director of program design. Some of her previous roles also include director of proposals and new technology for Gallus BioPharmaceuticals, Inc., and scientist, molecular oncology for Biogen Idec. She received her B.S. in biology from the University of California, San Diego, and holds a Ph.D. in cell and molecular biology from San Diego State University and the University of California, San Diego.